PCM
MYGN icon

Polymer Capital Management’s Myriad Genetics MYGN Stock Holding History

Polymer Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$97.8K Buy
+17,129
New +$77.7K 0.01% 580
2025
Q3 		– Sell
-20,795
Closed -$110K – 882
2025
Q2 		$110K Buy
20,795
+7,790
+60% +$46K 0.01% 582
2025
Q1 		$115K Sell
13,005
-38
-0.3% -$456 0.03% 469
2024
Q4 		$179K Buy
+13,043
New +$241K 0.05% 319

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Polymer Capital Management's MYGN Position: Q2 2026 in Review

Polymer Capital Management opened a new position in Myriad Genetics (MYGN) in Q2 2026: 17,129 shares worth $97.8K. The stake represents 0.01% of the portfolio and ranks #580 among its holdings. This is a return to the name: Polymer Capital Management previously reported a position in MYGN as recently as Q2 2025.

Polymer Capital Management first reported a position in MYGN in Q4 2024 and has held it in 4 quarters since. The position peaked at $179K in Q4 2024. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Polymer Capital Management held 17,129 shares of Myriad Genetics worth $97.8K as of Q2 2026.
  • Myriad Genetics was a new Polymer Capital Management position in Q2 2026.
  • Myriad Genetics made up 0.01% of Polymer Capital Management's portfolio in Q2 2026, its #580 holding.
  • Polymer Capital Management first reported a position in Myriad Genetics in Q4 2024 and has held it in 4 quarters since.
  • Polymer Capital Management's Myriad Genetics position peaked at $179K in Q4 2024.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Polymer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.